PARPi

From the Field

Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer

05/19/2022

Junxin Shi , PhD;

Yiqiong Xie , PhD, MPH;

Katrine L. Wallace , PhD;

Robert Reid , MD;

Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.

Dr Wallace and colleagues...

05/19/2022

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

March 23 ⁠–⁠ March 24

April 27 ⁠–⁠ April 28

Great Debates & Updates in Diabetic Foot

November 30 ⁠–⁠ December 2

November 27 ⁠–⁠ November 29

December 12 ⁠–⁠ December 13

May 13 ⁠–⁠ May 14

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

PARPi

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products